{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:04:25Z","timestamp":1787497465072,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T00:00:00Z","timestamp":1412208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>The<\/jats:bold>\n                      <jats:bold>Wisteria floribunda<\/jats:bold>\n                      <jats:bold>agglutinin-positive human Mac-2-binding protein (WFA+-M2BP) was recently shown to be a liver fibrosis glycobiomarker with a unique fibrosis-related glycoalteration. We evaluated the ability of WFA+-M2BP to predict the development of hepatocellular carcinoma (HCC) in patients who were infected with the hepatitis C virus (HCV). A total of 707 patients who had been admitted to our hospital with chronic HCV infection without other potential risk factors were evaluated to determine the ability of WFA+-M2BP to predict the development of HCC; factors evaluated included age, sex, viral load, genotypes, fibrosis stage, aspartate and alanine aminotransferase levels, bilirubin, albumin, platelet count, alpha-fetoprotein (AFP), WFA+-M2BP, and the response to interferon (IFN) therapy. Serum WFA+-M2BP levels were significantly increased according to the progression of liver fibrosis stage (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>&lt; 0.001). In each distinctive stage of fibrosis (F0-F1, F2, F3, and F4), the risk of development of HCC was increased according to the elevation of WFA+-M2BP. Multivariate analysis identified age<\/jats:bold>\n                      <jats:bold>&gt;<\/jats:bold>\n                      <jats:bold>57 years, F4, AFP<\/jats:bold>\n                      <jats:bold>&gt;<\/jats:bold>\n                      <jats:bold>20 ng\/mL, WFA+-M2BP \u22654, and WFA+-M2BP 1-4 as well as the response to IFN (no therapy vs. sustained virological response) as independent risk factors for the development of HCC. The time-dependent areas under the receiver operating characteristic curve demonstrated that the WFA+-M2BP assay predicted the development of HCC with higher diagnostic accuracy than AFP.<\/jats:bold>\n                      <jats:bold>Conclusion<\/jats:bold>\n                      <jats:bold>: WFA+-M2BP can be applied as a useful surrogate marker for the risk of HCC development, in addition to liver biopsy. (Hepatology 2014;60:1563\u20131570)<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.27305","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T11:35:21Z","timestamp":1405424121000},"page":"1563-1570","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":224,"title":["Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients"],"prefix":"10.1097","volume":"60","author":[{"given":"Kazumi","family":"Yamasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakuni","family":"Tateyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Abiru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsumasa","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemune","family":"Bekki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Miyazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Korenaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Togayachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ocho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Narimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20250207","doi-asserted-by":"crossref","first-page":"174181","DOI":"10.7326\/0003-4819-131-3-199908030-00003","article-title":"Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.","volume":"131","author":"Yoshida","year":"1999","journal-title":"Ann Intern Med"},{"key":"R3-17-20250207","doi-asserted-by":"crossref","first-page":"251259","DOI":"10.1136\/gut.48.2.251","article-title":"Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.","volume":"48","author":"Bolondi","year":"2001","journal-title":"Gut"},{"key":"R4-17-20250207","doi-asserted-by":"crossref","first-page":"196200","DOI":"10.1053\/jhep.2001.20534","article-title":"The role of liver biopsy in chronic hepatitis C.","volume":"33","author":"Saadeh","year":"2001","journal-title":"Hepatology"},{"key":"R5-17-20250207","doi-asserted-by":"crossref","first-page":"S161S172","DOI":"10.1002\/hep.1840360721","article-title":"Role of liver biopsy in management of chronic hepatitis C: a systematic review.","volume":"36","author":"Gebo","year":"2002","journal-title":"Hepatology"},{"key":"R6-17-20250207","doi-asserted-by":"crossref","first-page":"477481","DOI":"10.1053\/jhep.2000.16602","article-title":"Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).","volume":"32","author":"Cadranel","year":"2000","journal-title":"Hepatology"},{"key":"R8-17-20250207","first-page":"1065","article-title":"A serum sweetdoughnut 272 protein facilitates fibrosis evaluation and therapy assessment in patients 273 with viral hepatitis. Sci.","volume":"3","author":"Kuno","year":"2013","journal-title":"Rep"},{"key":"R9-17-20250207","doi-asserted-by":"crossref","first-page":"e91079","DOI":"10.1371\/journal.pone.0091079","article-title":"IgA nephropathy caused by unusual polymerization of IgA1 with aberrant Nglycosylation in a patient with monoclonal immunoglobulin deposition disease.","volume":"9","author":"Narimatsu","year":"2014","journal-title":"PloS One"},{"key":"R10-17-20250207","doi-asserted-by":"crossref","first-page":"16061613","DOI":"10.1093\/emboj\/17.6.1606","article-title":"Mac2 binding protein is a celladhesive protein of the extracellular matrix which selfassembles into ringlike structures and binds beta1 integrins, collagens and fibronectin.","volume":"17","author":"Sasaki","year":"1998","journal-title":"EMBO J"},{"key":"R11-17-20250207","first-page":"961965","article-title":"Serum 90KMAC2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alphafetoprotein.","volume":"39","author":"Iacovazzi","year":"2005","journal-title":"Clin Chem Lab Med"},{"key":"R12-17-20250207","doi-asserted-by":"crossref","first-page":"212217","DOI":"10.1016\/S0168-8278(96)80076-6","article-title":"Elevated serum levels of 90KMAC2 BP predict unresponsiveness to alphainterferon therapy in chronic HCV hepatitis patients.","volume":"25","author":"Artini","year":"1996","journal-title":"J Hepatol"},{"key":"R13-17-20250207","doi-asserted-by":"crossref","first-page":"418429","DOI":"10.1111\/j.1365-2893.2009.01083.x","article-title":"The HCV serum proteome: a search for fibrosis protein markers.","volume":"16","author":"Cheung","year":"2009","journal-title":"J Viral Hepat"},{"key":"R14-17-20250207","doi-asserted-by":"crossref","first-page":"642647","DOI":"10.1002\/prca.201300010","article-title":"Reconstruction of a robust glycodiagnostic agent supported by multiple lectinassisted glycan profiling.","volume":"7","author":"Kuno","year":"2013","journal-title":"Proteomics Clin Appl"},{"key":"R15-17-20250207","doi-asserted-by":"crossref","first-page":"92100","DOI":"10.1007\/s00535-010-0293-6","article-title":"Alphafetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.","volume":"46","author":"Tateyama","year":"2011","journal-title":"J Gastroenterol"},{"key":"R16-17-20250207","doi-asserted-by":"crossref","first-page":"15131520","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: diagnosis, grading and staging.","volume":"19","author":"Desmet","year":"1994","journal-title":"Hepatology"},{"key":"R17-17-20250207","doi-asserted-by":"crossref","first-page":"388393","DOI":"10.1053\/jhep.2000.9112","article-title":"Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA.","volume":"32","author":"Tanaka","year":"2000","journal-title":"Hepatology"},{"key":"R18-17-20250207","doi-asserted-by":"crossref","first-page":"201207","DOI":"10.1128\/jcm.35.1.201-207.1997","article-title":"New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a.","volume":"35","author":"Ohno","year":"1997","journal-title":"J Clin Microbiol"},{"key":"R19-17-20250207","doi-asserted-by":"crossref","first-page":"337344","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Timedependent ROC curves for censored survival data and a diagnostic marker.","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"R20-17-20250207","first-page":"13341340","article-title":"The longterm pathological evolution of chronic hepatitis C.","volume":"23","author":"Yano","year":"1996","journal-title":"Hepatology"},{"key":"R21-17-20250207","doi-asserted-by":"crossref","first-page":"196200","DOI":"10.1053\/jhep.2001.20534","article-title":"The role of liver biopsy in chronic hepatitis C.","volume":"33","author":"Saadeh","year":"2001","journal-title":"Hepatology"},{"key":"R23-17-20250207","doi-asserted-by":"crossref","first-page":"495500","DOI":"10.1056\/NEJM200102153440706","article-title":"Liver biopsy.","volume":"344","author":"Bravo","year":"2001","journal-title":"N Engl J Med"},{"key":"R24-17-20250207","doi-asserted-by":"crossref","first-page":"825832","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C.","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"R25-17-20250207","first-page":"14491457","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C.","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"},{"key":"R26-17-20250207","doi-asserted-by":"crossref","first-page":"477481","DOI":"10.1053\/jhep.2000.16602","article-title":"Practices of liver biopsy in France: results of a prospective nationwide survey.","volume":"32","author":"Cadranel","year":"2000","journal-title":"Hepatology"},{"key":"R27-17-20250207","doi-asserted-by":"crossref","first-page":"17051713","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"key":"R28-17-20250207","doi-asserted-by":"crossref","first-page":"343350","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.","volume":"128","author":"Castera","year":"2005","journal-title":"Gastroenterology"},{"key":"R29-17-20250207","doi-asserted-by":"crossref","first-page":"10131021","DOI":"10.1016\/j.jhep.2010.05.035","article-title":"Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).","volume":"53","author":"Degos","year":"2010","journal-title":"J Hepatol"},{"key":"R30-17-20250207","doi-asserted-by":"crossref","first-page":"281287","DOI":"10.1016\/j.jhep.2012.03.016","article-title":"ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study.","volume":"57","author":"Crespo","year":"2012","journal-title":"J Hepatol"},{"key":"R31-17-20250207","doi-asserted-by":"crossref","first-page":"930938","DOI":"10.1016\/S0168-8278(98)80339-5","article-title":"Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients.","volume":"28","author":"Ikeda","year":"1998","journal-title":"J Hepatol"},{"key":"R32-17-20250207","doi-asserted-by":"crossref","first-page":"459464","DOI":"10.1016\/j.cgh.2008.02.012","article-title":"Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients.","volume":"6","author":"Ohki","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R33-17-20250207","doi-asserted-by":"crossref","first-page":"650655","DOI":"10.1002\/hep.1840210308","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients.","volume":"21","author":"Takano","year":"1995","journal-title":"Hepatology"},{"key":"R34-17-20250207","doi-asserted-by":"crossref","first-page":"268275","DOI":"10.1046\/j.1365-2893.2000.00235.x","article-title":"Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type Ca study of 527 patients at one establishment.","volume":"7","author":"Matsumura","year":"2000","journal-title":"J Viral Hepat"},{"key":"R35-17-20250207","doi-asserted-by":"crossref","first-page":"131136","DOI":"10.1136\/gut.47.1.131","article-title":"Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.","volume":"47","author":"Degos","year":"2000","journal-title":"Gut"},{"key":"R36-17-20250207","first-page":"197203","article-title":"Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virusrelated cirrhosis: a longterm followup study.","volume":"19","author":"RodriguezDiaz","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R37-17-20250207","doi-asserted-by":"crossref","first-page":"12081236","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma.","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"R38-17-20250207","doi-asserted-by":"crossref","first-page":"675680","DOI":"10.1056\/NEJM199109053251002","article-title":"Hepatocellular carcinoma in Italian patients with cirrhosis.","volume":"325","author":"Colombo","year":"1991","journal-title":"N Engl J Med"},{"key":"R39-17-20250207","doi-asserted-by":"crossref","first-page":"17971801","DOI":"10.1056\/NEJM199306243282501","article-title":"Risk factors for hepatocellular carcinoma among patients with chronic liver disease.","volume":"328","author":"Tsukuma","year":"1993","journal-title":"N Engl J Med"},{"key":"R40-17-20250207","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.1002\/hep.1840190111","article-title":"Prospective study of alphafetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma.","volume":"19","author":"Oka","year":"1994","journal-title":"Hepatology"},{"key":"R41-17-20250207","first-page":"11121118","article-title":"Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis.","volume":"23","author":"GanneCarrie","year":"1996","journal-title":"Hepatology"},{"key":"R42-17-20250207","doi-asserted-by":"crossref","first-page":"15751580","DOI":"10.1111\/j.1572-0241.2001.03780.x","article-title":"Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients.","volume":"96","author":"Sangiovanni","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R43-17-20250207","doi-asserted-by":"crossref","first-page":"10891097","DOI":"10.1016\/j.jhep.2006.02.008","article-title":"Prediction model of hepatocarcinogenesis for patients with hepatitis C virusrelated cirrhosis. Validation with internal and external cohorts.","volume":"44","author":"Ikeda","year":"2006","journal-title":"J Hepatol"},{"key":"R44-17-20250207","doi-asserted-by":"crossref","first-page":"179187","DOI":"10.1111\/j.1365-2893.2007.00928.x","article-title":"Clinical significance of elevated alphafetoprotein in Alaskan Native patients with chronic hepatitis C.","volume":"15","author":"Bruce","year":"2008","journal-title":"J Viral Hepat"},{"key":"R45-17-20250207","doi-asserted-by":"crossref","first-page":"234240","DOI":"10.2188\/jea.10.234","article-title":"Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis.","volume":"10","author":"Inoue","year":"2000","journal-title":"J Epidemiol"},{"key":"R46-17-20250207","doi-asserted-by":"crossref","first-page":"589595","DOI":"10.1002\/(SICI)1097-0142(19990815)86:4<589::AID-CNCR7>3.0.CO;2-K","article-title":"Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virusassociated cirrhosis.","volume":"86","author":"Tarao","year":"1999","journal-title":"Cancer"},{"key":"R47-17-20250207","doi-asserted-by":"crossref","first-page":"17871795","DOI":"10.1002\/cncr.10391","article-title":"Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virusassociated cirrhosis.","volume":"94","author":"Tarao","year":"2002","journal-title":"Cancer"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.27305","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.27305","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.27305","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201411000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:50:02Z","timestamp":1738929002000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201411000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.27305","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}